8-K: Neurocrine Biosciences Reports Q1 2025 Financial Results, Reaffirms Guidance

Neurocrine Biosciences announces first quarter 2025 financial results, including INGREZZA net product sales of $545 million, and reaffirms its 2025 financial guidance.

Summary

• Neurocrine Biosciences announced its financial results for the first quarter ended March 31, 2025.
• INGREZZA net product sales for Q1 2025 were $545 million, an 8% increase compared to Q1 2024.
• CRENESSITY net product sales for Q1 2025 were $14.5 million, with 413 total patient enrollment start forms.
• The company is reaffirming its 2025 INGREZZA net sales guidance of $2.5 to $2.6 billion.
• Neurocrine initiated Phase 3 registrational programs for osavampator in major depressive disorder and NBI-568 in schizophrenia.
• GAAP net income for Q1 2025 was $7.9 million, or $0.08 per share diluted, compared to $43.4 million, or $0.42 per share diluted, for Q1 2024.
• Non-GAAP net income for Q1 2025 was $71.5 million, or $0.70 per share diluted, compared to $124.8 million, or $1.20 per share diluted, for Q1 2024.
• The company had approximately $1.8 billion in cash, cash equivalents, and marketable securities as of March 31, 2025.
• A $300 million accelerated share repurchase program was completed on February 5, 2025.
• A second share repurchase program to repurchase up to $500 million of outstanding common stock was announced on February 21, 2025, with $150 million repurchased as of March 31, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue growth is present, the decrease in net income raises concerns. The reaffirmation of guidance and pipeline advancements provide a positive outlook.

Positives

• INGREZZA sales increased by 8% year-over-year, reaching $545 million in Q1 2025.
• CRENESSITY launch shows strong initial patient demand with $14.5 million in net product sales and 413 patient enrollment start forms.
• The company reaffirmed its 2025 INGREZZA net sales guidance of $2.5 to $2.6 billion.
• Phase 3 programs initiated for osavampator in MDD and NBI-568 in schizophrenia, positioning the company for future growth.
• The company has a strong balance sheet with approximately $1.8 billion in cash, cash equivalents, and marketable securities.
• Expanded formulary access for INGREZZA, significantly improving coverage to now include two-thirds of tardive dyskinesia and Huntingtons disease Medicare beneficiaries.

Negatives

• GAAP net income decreased from $43.4 million in Q1 2024 to $7.9 million in Q1 2025.
• Non-GAAP net income decreased from $124.8 million in Q1 2024 to $71.5 million in Q1 2025.
• Increased R&D and SG&A expenses impacted net income.
• The company experienced a $31 million loss from changes in fair values of equity investments compared to a $2 million gain in the same period last year.

Risks

• The company's future financial performance depends on the continued success of INGREZZA and the successful launch of CRENESSITY.
• The development of product candidates is subject to risks, including regulatory approvals, clinical trial outcomes, and manufacturing challenges.
• The company is dependent on third parties for development, manufacturing, and commercialization activities.
• Government and third-party regulatory and/or policy efforts may impose sales and pharmaceutical pricing controls.
• The company faces competition from other therapies or products, including potential generic entrants.

Future Outlook

Neurocrine Biosciences reaffirms its full-year 2025 financial guidance, including INGREZZA net product sales of $2.5 to $2.6 billion, GAAP R&D expense of $960 to $1,010 million, Non-GAAP R&D expense of $890 to $940 million, GAAP SG&A expense of $1,110 to $1,130 million, and Non-GAAP SG&A expense of $955 to $975 million.

Management Comments

• Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences, stated that the company delivered a record number of new patient starts for INGREZZA, which is especially impressive given the typically challenging first quarter.
• Dr. Gano also noted that the combination of INGREZZA and CRENESSITY provides a solid foundation for nearand long-term revenue growth.
• Dr. Gano added that Neurocrine is well positioned to deliver sustained growth and innovation in neuroscience with registrational programs for osavampator and NBI-568 ongoing, an advancing early-to-mid-stage pipeline, and a strong balance sheet.

Industry Context

Neurocrine's focus on neuroscience and its diverse portfolio of treatments for neuropsychiatric, neurological, and neuroendocrine disorders positions it well in a growing market. The successful commercialization of INGREZZA and the launch of CRENESSITY demonstrate the company's ability to bring innovative treatments to patients with unmet needs. The initiation of Phase 3 programs for osavampator and NBI-568 further strengthens the company's pipeline and growth potential.

Comparison to Industry Standards

• Neurocrine's INGREZZA sales growth of 8% year-over-year is a solid performance in the context of the pharmaceutical industry, where growth rates can vary significantly depending on the product and market conditions.
• Companies like Teva Pharmaceuticals, which also has a presence in the tardive dyskinesia market, may be considered competitors, and their performance can provide a benchmark for Neurocrine's growth.
• The successful launch of CRENESSITY and its initial sales of $14.5 million demonstrate a strong start compared to other rare disease drug launches.
• The company's R&D investment reflects its commitment to innovation and pipeline development, which is comparable to other biopharmaceutical companies focused on neuroscience, such as Biogen and Ionis Pharmaceuticals.

Management Changes

Stakeholder Impact

• Shareholders: Impacted by financial performance, share repurchase program, and pipeline progress.
• Employees: Affected by headcount investments and company growth.
• Patients: Benefit from the availability of INGREZZA and CRENESSITY, as well as the development of new treatments.
• Collaboration Partners: Impacted by the progress of collaborative programs and achievement of milestones.

Next Steps

• Continue commercialization efforts for INGREZZA and CRENESSITY.
• Advance Phase 3 registrational programs for osavampator in MDD and NBI-568 in schizophrenia.
• Continue Phase 1 clinical studies for NBI-921355 and NBI-1140675.
• Monitor and manage expenses to improve profitability.
• Continue share repurchase program.

Key Dates

Keywords

Neurocrine Biosciences, INGREZZA, CRENESSITY, Financial Results, Q1 2025, Net Product Sales, Guidance, Clinical Trials, Share Repurchase, Neuroscience